Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 5Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Hepatoblastoma 1Adrenocortical Carcinoma 1

Interventions

Filgrastim 13Carboplatin 10Cyclophosphamide 9pembrolizumab 8Radiosurgery 8Ifosfamide 8Magnetic Resonance Spectroscopy 7Etoposide 7Biopsy 7Specimen Handling 6Doxorubicin 6X-Rays 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Paclitaxel 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cisplatin 5pazopanib 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Nivolumab 4Mesna 4Melphalan 4Docetaxel 4Busulfan 4Blood Specimen Collection 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × cixutumumab × Genitourinary × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡